Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Dec 17, 2024

BUY
$7.63 - $12.66 $25,179 - $41,778
3,300 New
3,300 $29.4 Million
Q1 2024

Dec 04, 2024

BUY
$8.6 - $11.9 $50,740 - $70,210
5,900 New
5,900 $59.8 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $922M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Catalyst Funds Management Pty LTD Portfolio

Follow Catalyst Funds Management Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Funds Management Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Funds Management Pty LTD with notifications on news.